FDA Tracker newsroom · Peptide reclassification (RFK-14)

What the RFK-14 peptide reclassification actually means.

Apr 22, 2026 · Last reviewed Jun 16, 2026

“RFK-14” is shorthand for the group of peptides swept into the 2026 compounding-policy review. Reclassification changes how, and whether, a licensed pharmacy may compound them. It is a regulatory mechanism, not a clinical endorsement.

The “RFK-14” shorthand refers to the group of peptides caught up in the 2026 compounding-policy review. Reclassification changes how, and whether, a licensed pharmacy may compound a molecule for an individual patient.

Reclassification is a regulatory mechanism, not a clinical endorsement. A molecule can move between categories without any new efficacy or safety evidence, the science and the paperwork move on separate tracks.

We track each molecule's category and translate it into the one thing a non-expert actually needs: can you get it, today, legitimately. That is the verdict dot; the category and pill carry the precise regulatory detail beside it.

Molecules in this update

• BPC-157 — FDA status
• TB-500 — FDA status
• KPV — FDA status
• CJC-1295 — FDA status
• Ipamorelin — FDA status

Primary sources

• FDA human drug compounding, categories
• Compounding docket FDA-2026-N-2979

Reviewed by the Peptós.LIFE clinical team · Medical & regulatory review.

Compounded medications are not FDA-approved. PCAC is an advisory committee: a favorable vote leads to FDA rulemaking, not authorization and not next-day availability. Nothing here is medical advice, and no peptide is offered for sale on this page.

Get the alert when this status actually changes · Full FDA status board · All regulatory updates